Healthcare Industry News: HSMN NewsFeed

Biopharmaceuticals Personnel

 News Release - December 28, 2016

Concordia International Corp. Announces Leadership Transition at International Segment

OAKVILLE, ON, Dec. 28, 2016 -- (Healthcare Sales & Marketing Network) - Concordia International Corp. ("Concordia" or the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that effective January 1, 2017, John Beighton will retire from his current role as President of the Company's International segment.

Graeme Duncan, currently Managing Director for the segment, will replace Mr. Beighton as President. Mr. Beighton will remain with Concordia as a board member of the Company's International segment, where he will continue to be available to provide strategic advice to the International business.

"We are grateful to John for his contribution towards building a global business with significant product and geographic diversity, and we wish him well in his retirement," said Allan Oberman, Chief Executive Officer of Concordia. "As we look ahead, we are confident that Graeme's deep knowledge of the industry and his broad strategic experience will help him thrive in his new leadership role."

Mr. Duncan joined Amdipharm Mercury Limited (now Concordia's International segment) in 2015 as Global Marketing Director and Vice President, Commercial UK and Ireland. He was promoted to Managing Director in 2016 and was responsible for the general management of the segment.

Mr. Duncan has worked for 20 years in the life sciences sector within the areas of strategy, sales and marketing, and management. Prior to Concordia, Mr. Duncan held senior management roles in GlaxoWellcome, GlaxoSmithKline, IVAX Pharmaceuticals and Healthcare at Home.

Concordia's International segment operates as an international specialty pharmaceutical company, supplying a broad portfolio of branded and generic prescription medicines to wholesalers, hospitals and pharmacies in more than 100 countries.

About Concordia

Concordia is a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs. The Company has an international footprint with sales in more than 100 countries, and has a diversified portfolio of more than 200 established, off-patent molecules that make up more than 1,300 SKUs. Concordia also markets orphan drugs through its Orphan Drugs Division, consisting of PhotofrinŽ for the treatment of certain rare forms of cancer.

Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.

Notice regarding forward-looking statements and information

This press release includes forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws, regarding Concordia and its business, which may include, but are not limited to the confidence in members of management in new roles and their success in such roles. Often, but not always, forward-looking statements and forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of Concordia's management, and are based on assumptions and subject to risks and uncertainties. Although Concordia's management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks relating to the inability to develop a new strategic plan and/or implement the Company's key priorities, the inability of management to succeed in new roles or have a positive impact on the business of the Company, Concordia's securities, risks associated with developing new product indications, increased indebtedness and leverage, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically, the inability to repay debt and/or satisfy future obligations (including, without limitation, earn out obligations), risks associated with Concordia's outstanding debt, risks associated with the geographic markets in which Concordia operates and/or distributes its products, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks associated with the use of Concordia's products to treat certain diseases, the pharmaceutical industry and the regulation thereof, regulatory investigations, the failure to comply with applicable laws, risks relating to distribution arrangements, possible failure to realize the anticipated benefits of acquisitions and/or product launches, risks associated with the integration of assets and businesses into Concordia's business, product launches, the inability to launch products, the fact that historical and projected financial information may not be representative of Concordia's future results, the failure to obtain regulatory approvals, economic factors, market conditions, acquisition opportunities, risks associated with the acquisition and/or launch of pharmaceutical products, risks regarding clinical trials and/or patient enrollment into clinical trials, the equity and debt markets generally, risks associated with growth and competition (including, without limitation, with respect to Concordia's niche, hard-to-make products), general economic and stock market conditions, risks associated with the United Kingdom's exit from the European Union (including, without limitation, risks associated with regulatory changes in the pharmaceutical industry, changes in cross-border tariff and cost structures and the loss of access to the European Union global trade markets), risks related to patent infringement actions, the loss of intellectual property rights, risks and uncertainties detailed from time to time in Concordia's filings with the Securities and Exchange Commission and the Canadian Securities Administrators and many other factors beyond the control of Concordia. Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and forward-looking information speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward-looking statement or forward-looking information, whether as a result of new information, future events, or otherwise.


Source: Concordia International

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.RepFinder 2 - available on the Apple App Store for iPhone and iPad.